GOSS Nasdaq Pharmaceutical Preparations Financials FY2017βFY2025
Gossamer Bio, Inc. had $48.5M of revenue in fiscal 2025, down 57.7% on the year before.
Last close Β· Oct 23, 2026
$9.61
1.5%Hi! I read Gossamer Bio, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β57.7%
No. Sales fell 57.7% last year.
Does it make a profit?
β351.5%
No. It lost money last year.
Does profit turn into cash?
β353.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Gossamer Bio, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 23, 2026 | Q2 '26 | Time not announced | 8-K β |
| May 15, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Mar 17, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 5, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 5, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 15, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 13, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 7, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Gossamer Bio, Inc. had $48.5M of revenue in fiscal 2025, down 57.7% on the year before. Its operating margin was β352.2%, down 300.0Β pts: of every 100 in sales, about β352 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Gossamer Bio, Inc. lost $170M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$171M in fiscal 2025, β353.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Gossamer Bio, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $325M | $256M | $296M | $295M | $137M |
| Debt incl. finance leases | $29.1M | $23.6M | $12.4M | $0.0M | β |
| Debt / equity | 0.2x | 2.0x | 0.2x | 0.0x | β |
| Interest coverage | β11.1x | β15.7x | β13.6x | β5.2x | β15.5x |
| Current ratio | 8.3x | 5.3x | 5.9x | 6.9x | 2.6x |
| Quick ratio | 8.3x | 5.3x | 5.9x | 6.9x | 2.6x |
| Total assets | $344M | $272M | $312M | $315M | $172M |
| Total liabilities | $222M | $260M | $249M | $286M | $295M |
| Shareholders' equity | $121M | $12.1M | $62.8M | $29.5M | β$123M |
| Net debt (β = net cash) | β$296M | β$232M | β$284M | β$295M | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Gossamer Bio, Inc. passes 0 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | β / 6 | 3 / 7 | 1 / 7 | 1 / 7 | 4 / 8 | 5 / 8 | 0 / 7 |
| Accruals ratio | β | β40.1% | β10.7% | β13.9% | β10.2% | β13.7% | β7.1% | β16.9% | 0.4% |
| Altman Z'' | β | β6.45 | 5.23 | 1.02 | β5.78 | β12.57 | β11.00 | β8.77 | β30.36 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | β | β | β | β | β | $0.0M | $0.0M | $115M | $48.5M |
| Research and development | $0.9M | $55.3M | $143M | $161M | $170M | $171M | $135M | $138M | $174M |
| Operating income | β$6.7M | β$149M | β$186M | β$234M | β$216M | β$219M | β$184M | β$59.9M | β$171M |
| Interest expense | β | $0.0M | $1.9M | $12.7M | $19.4M | $13.9M | $13.5M | $11.5M | $11.0M |
| Pretax income | $6.8M | β$147M | β$180M | β$243M | β$234M | β$229M | β$180M | β$55.6M | β$170M |
| Income tax | $0.0M | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $0.9M | β$0.1M |
| Net income | β$6.8M | β$147M | β$180M | β$243M | β$234M | β$229M | β$180M | β$56.5M | β$170M |
| Diluted EPS | β$0.74 | β$22.59 | β$3.29 | β$3.55 | β$3.13 | β$2.71 | β$1.18 | β$0.25 | β$0.75 |
| Diluted shares | 0.01B | 0.01B | 0.05B | 0.07B | 0.07B | 0.08B | 0.15B | 0.23B | 0.23B |
| Cash flow | |||||||||
| Cash from operations | β$5.7M | β$51.0M | β$145M | β$176M | β$189M | β$187M | β$159M | β$3.5M | β$171M |
| Capital expenditure | β | $3.5M | $3.0M | $1.5M | $1.5M | $0.4M | $0.0M | $0.0M | $0.1M |
| Free cash flow | β | β$54.5M | β$148M | β$178M | β$190M | β$187M | β$159M | β$3.5M | β$171M |
| Depreciation and amortization | $0.0M | $0.3M | $0.9M | $1.4M | $1.7M | $1.8M | $1.6M | $0.8M | $0.0M |
| Stock-based compensation | $0.0M | $30.9M | $20.8M | $38.7M | $32.0M | $42.6M | $28.5M | $20.6M | $10.6M |
| Balance sheet | |||||||||
| Cash and short-term investments | $0.3M | $229M | $402M | $513M | $325M | $256M | $296M | $295M | $137M |
| Total debt | β | β | $28.5M | $28.7M | $29.1M | $23.6M | $12.4M | $0.0M | β |
| Current assets | β | $232M | $409M | $522M | $332M | $262M | $307M | $310M | $168M |
| Current liabilities | β | $20.4M | $36.9M | $38.7M | $39.9M | $49.2M | $51.6M | $45.0M | $63.4M |
| Property and equipment, net | β | $3.2M | $5.4M | $5.5M | $5.3M | $4.0M | $1.6M | $0.0M | $0.1M |
| Total assets | β | $239M | $427M | $539M | $344M | $272M | $312M | $315M | $172M |
| Total liabilities | β | $21.1M | $74.1M | $219M | $222M | $260M | $249M | $286M | $295M |
| Preferred stock | β | β | β | $0.0M | β | β | β | β | β |
| Shareholders' equity | β$6.9M | β$120M | $352M | $321M | $121M | $12.1M | $62.8M | $29.5M | β$123M |
| Margins | |||||||||
| Operating margin | β | β | β | β | β | β | β | β52.2% | β352.2% |
| EBITDA margin | β | β | β | β | β | β | β | β51.5% | β352.2% |
| Net margin | β | β | β | β | β | β | β | β49.3% | β351.5% |
| FCF margin | β | β | β | β | β | β | β | β3.0% | β353.5% |
| Returns | |||||||||
| Return on capital employed | β | β68.0% | β47.8% | β46.7% | β71.1% | β97.9% | β70.6% | β22.2% | β156.9% |
| Return on equity | β | β | β155.2% | β72.3% | β105.8% | β343.5% | β480.5% | β122.5% | β |
| Return on assets | β | β61.4% | β54.1% | β50.4% | β53.0% | β74.5% | β61.5% | β18.0% | β69.9% |
| Return on tangible equity | β | β | β51.2% | β75.9% | β192.7% | β1,899.3% | β286.5% | β191.7% | β |
| Growth | |||||||||
| Revenue growth | β | β | β | β | β | β | β | β | β57.7% |
| Share count change | β | β29.0% | 741.5% | 25.2% | 9.2% | 13.0% | 80.5% | 48.2% | 1.0% |
| Financial health | |||||||||
| Debt / equity | β | β | 0.1x | 0.1x | 0.2x | 2.0x | 0.2x | 0.0x | β |
| Interest coverage | β | β12,416.1x | β96.0x | β18.5x | β11.1x | β15.7x | β13.6x | β5.2x | β15.5x |
| Current ratio | β | 11.4x | 11.1x | 13.5x | 8.3x | 5.3x | 5.9x | 6.9x | 2.6x |
| Quick ratio | β | 11.4x | 11.1x | 13.5x | 8.3x | 5.3x | 5.9x | 6.9x | 2.6x |
| Capital allocation | |||||||||
| Capex / revenue | β | β | β | β | β | β | β | 0.0% | 0.2% |
| Stock comp / revenue | β | β | β | β | β | β | β | 18.0% | 21.8% |
| Quality scores | |||||||||
| Piotroski F-score | β | β | β | 3.0 | 1.0 | 1.0 | 4.0 | 5.0 | 0.0 |
| Altman Z'' | β | β6.4 | 5.2 | 1.0 | β5.8 | β12.6 | β11.0 | β8.8 | β30.4 |
| Accruals ratio | β | β40.1% | β10.7% | β13.9% | β10.2% | β13.7% | β7.1% | β16.9% | 0.4% |
Source: SEC EDGAR XBRL filings (CIK 0001728117). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
